Target
E3 ubiquitin-protein ligase Mdm2 [17-125]
Ligand
BDBM227653
Substrate
n/a
Meas. Tech.
FRET Assay
Temperature
298.15±n/a K
IC50
0.156±n/a nM
Comments
extracted
Citation
 Cammarano, CMChristopher, MPDinsmore, CDoll, RJFradera Llinas, FXLi, CMachacek, MMartinez, MNair, LGPan, WReutershan, MHShizuka, MSteinhuebel, DPSun, BThompson, CFTrotter, BWWang, YYang, LBogen, SLVoss, MEPanda, JKurissery, AT 2,6,7,8 substituted purines as HDM2 inhibitors US Patent  US9540377 Publication Date 1/10/2017 
Target
Name:
E3 ubiquitin-protein ligase Mdm2 [17-125]
Synonyms:
Double minute 2 protein | E3 ubiquitin-protein ligase Mdm2 | MDM2 | MDM2_HUMAN | p53-binding protein Mdm2
Type:
Enzyme Catalytic Domain
Mol. Mass.:
12522.24
Organism:
Homo sapiens (Human)
Description:
Residue 17 to 125
Residue:
109
Sequence:
SQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSEN
  
Inhibitor
Name:
BDBM227653
Synonyms:
3-{6-(5-chloropyridin-3- yl)-8-[1-(2,6- difluorophenyl)-1- fluoroethyl]-7-[(trans-4- methylcyclohexyl)methyl]- 7h-purin-2-yl}-1,2,4- oxadiazol-5(4h)-one (enantiomer 1) | US9540377, 23.68 | US9540377, 23.69
Type:
Small organic molecule
Emp. Form.:
C28H25ClF3N7O2
Mol. Mass.:
583.992
SMILES:
C[C@H]1CC[C@H](Cn2c(nc3nc(nc(-c4cncc(Cl)c4)c23)-c2noc(=O)[nH]2)C(C)(F)c2c(F)cccc2F)CC1 |r,wU:4.4,wD:1.0,(7.09,-3.69,;5.6,-3.29,;5.21,-1.81,;3.72,-1.41,;2.63,-2.5,;1.14,-2.1,;.74,-.61,;1.65,.64,;.74,1.88,;-.72,1.41,;-2.05,2.18,;-3.39,1.41,;-3.39,-.13,;-2.05,-.9,;-2.05,-2.44,;-.72,-3.21,;-.72,-4.75,;-2.05,-5.52,;-3.39,-4.75,;-4.72,-5.52,;-3.39,-3.21,;-.72,-.13,;-4.72,2.18,;-6.19,1.7,;-7.09,2.95,;-6.19,4.19,;-6.96,5.52,;-4.72,3.72,;3.31,.64,;4.08,-.7,;4.85,.64,;4.08,1.97,;3.31,3.3,;1.77,3.3,;4.08,4.64,;5.62,4.64,;6.39,3.3,;5.62,1.97,;6.39,.64,;3.03,-3.98,;4.52,-4.38,)|
Structure:
Search PDB for entries with ligand similarity: